FDA Approves Kresladi, First Gene Therapy for Severe LAD-I

Fri, 27 Mar 2026 03:16:26 +0000
Pharmaceuticals

The FDA has approved Kresladi (marnetegragene autotemcel), the first gene therapy for severe Leukocyte Adhesion Deficiency Type I (LAD-I) in pediatric patients. This accelerated approval offers a new treatment option for a rare inherited immune deficiency, targeting the underlying genetic cause of the disease.